Dock3 attenuates neural cell death due to NMDA neurotoxicity and oxidative stress in a mouse model of normal tension glaucoma

被引:0
作者
K Namekata
A Kimura
K Kawamura
X Guo
C Harada
K Tanaka
T Harada
机构
[1] Visual Research Project,
[2] Tokyo Metropolitan Institute of Medical Science,undefined
[3] Laboratory of Molecular Neuroscience,undefined
[4] School of Biomedical Science and Medical Research Institute,undefined
[5] Tokyo Medical and Dental University,undefined
来源
Cell Death & Differentiation | 2013年 / 20卷
关键词
Dock3; glutamate; oxidative stress; neuroprotection; glaucoma;
D O I
暂无
中图分类号
学科分类号
摘要
Dedicator of cytokinesis 3 (Dock3), a new member of the guanine nucleotide exchange factors for the small GTPase Rac1, promotes axon regeneration following optic nerve injury. In the present study, we found that Dock3 directly binds to the intracellular C-terminus domain of NR2B, an N-methyl-D-aspartate (NMDA) receptor subunit. In transgenic mice overexpressing Dock3 (Dock3 Tg), NR2B expression in the retina was significantly decreased and NMDA-induced retinal degeneration was ameliorated. In addition, overexpression of Dock3 protected retinal ganglion cells (RGCs) from oxidative stress. We previously reported that glutamate/aspartate transporter (GLAST) is a major glutamate transporter in the retina, and RGC degeneration due to glutamate neurotoxicity and oxidative stress is observed in GLAST-deficient (KO) mice. In GLAST KO mice, the NR2B phosphorylation rate in the retina was significantly higher compared with Dock3 Tg:GLAST KO mice. Consistently, glaucomatous retinal degeneration was significantly improved in GLAST KO:Dock3 Tg mice compared with GLAST KO mice. These results suggest that Dock3 overexpression prevents glaucomatous retinal degeneration by suppressing both NR2B-mediated glutamate neurotoxicity and oxidative stress, and identifies Dock3 signaling as a potential therapeutic target for both neuroprotection and axonal regeneration.
引用
收藏
页码:1250 / 1256
页数:6
相关论文
共 268 条
  • [1] Christie MJ(2010)Dendritic function of tau mediates amyloid- Cell 142 387-397
  • [2] Napier IA(2007) toxicity in Alzheimer's disease mouse models J Neurosci 27 2866-2875
  • [3] Eckert A(2010)Natural oligomers of the Alzheimer amyloid- Neuron 65 178-190
  • [4] Staufenbiel M(2012) protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway Nat Rev Drug Discov 11 541-559
  • [5] Hardeman E(2009)Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice Trends Pharmacol Sci 30 563-569
  • [6] Götz J(2007)Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma J Clin Invest 117 1763-1770
  • [7] Shankar GM(2013)Glutamate-based antidepressants: 20 years on Nat Rev Neurosci 14 383-400
  • [8] Bloodgood BL(2009)The potential role of glutamate transporters in the pathogenesis of normal tension glaucoma J Neurosci 29 1469-1479
  • [9] Townsend M(1994)NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease Eur J Neurosci 6 1100-1112
  • [10] Walsh DM(1994)Coagonist release modulates NMDA receptor subtype contributions at synaptic inputs to retinal ganglion cells Brain Res 634 328-332